EUCTR2020-000569-18-FR进行中（未招募）1 期
EOADUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL - AB-LATE02
niversity Hospital of Montpellier0 个研究点目标入组 202 人开始时间: 2020年9月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients = 18 years of age
- •Diagnostic of HCC based on histology
- •Patients with HCC eligible for ablation as assessed by multidisciplinary board:
- •- All HCC nodules <3cm
- •- 1-3 nodules of HCC
- •At least one uni-dimensional measurable lesion by magnetic resonance imaging (MRI) according to modified RECIST criteria
- •Liver function status Child-Pugh Class A
- •Eastern Cooperative Oncology Group (ECOG) Performance Status = 1
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory tests:
- •- Hemoglobin > 8.5 g/dL
- •- Absolute neutrophil count = 1500/mm3
- •- Platelet count = 50,000/ mm3
- •- Total bilirubin = 2 mg/dL
- •- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 x upper limit of normal (ULN)
- •- Serum creatinine = 1.5 x ULN
- •- Lipase = 2 x ULN
- •- Prothrombin time > 50%
- •- Glomerular Filtration Rate (GFR) = 35 mL/min/1.73 m2
- •Life expectancy = 3 months
- •Women of childbearing potential and men must agree to use adequate contraception during the study and for 5 months after stopping Treatment
- •Patients affiliated to a Social Security System
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 182
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Patients with contraindications to ablation or atezolizumab or bevacizumab
- •- Patients with contraindication to contrast medium intravenous injection either gadolinium or iodinate
- •- Patients with contraindication to MRI
- •- Prior liver transplantation or candidates for liver transplantation
- •- Child-Pugh B or C
- •- Patients with mixed histology (HCC and cholangiocarcinoma, namely hepatocholangiocarcinoma)
- •- Treatment with anticoagulants (heparin or AVK) that cannot be interrupted for 48 hours
- •- Treatment with anti-platelets (especially aspirin, Plavix®) that cannot be interrupted for 5 days.
- •- Portal vein invasion, whatever its extent, shown on baseline imaging
- •- Prior chemoembolization or radioembolization.
- •- Patients with extra-hepatic metastases, either previously-treated or not. One lung nodule (<5mm) is allowed. Calcified lung micronodules as well as typical intra-pulmonary lymph nodes are allowed. Hepatic hilum lymph node < 10mm (short axis) is allowed.
- •- Prior surgery of HCC with micro- or macro-vascular invasion demonstrated at pathology.
- •- Prior systemic treatment for HCC, in particular agents targeting T-cell costimulation or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, CD137, or cytotoxic T-lymphocyte antigen [CTLA-4]).
- •- Patients with uncontrolled HBV infection and viral load above 500 IU/mL.
- •- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months of prior to initiation of study treatment do not need to repeat the procedure
- •- Past or concurrent history of neoplasm other than HCC, except for in-situ carcinoma of the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumors. Any cancer curatively treated > 3 years prior to study entry is permitted
- •- Known history or symptomatic meningeal tumors
- •- Grade 3 (severe) hypertension =160 and/or =100 mmHG (systolic and diastolic, according to NCI-CTCAE v5.0)
- •- Patients with phaeochromocytoma
- •- Ongoing infection. Hepatitis B is allowed if no active replication is present (HBV replication below 500 IU/mL). Hepatitis C is allowed if no antiviral treatment is required
- •- Clinically significant bleeding NCI-CTCAE version 5.0 = Grade 3 within 30 days before enrolment (transfusion indicated)
- •- Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 6 months before enrolment
- •- Any psychological, familial, sociological, geographical or illness or medical condition that could jeopardize the safety of the patient and/or his compliance with the study protocol and follow-up procedure
- •- Known history of human immunodeficiency virus (HIV) infection
- •- Seizure disorder requiring medication
- •- Non-healing wound, ulcer or bone fracture
- •- Breast feeding
- •- Pregnancy
- •- Legal incapacity (persons in custody or under guardianship)
- •- Deprived of liberty Subject (by judicial or administrative decision)
研究者
相似试验
招募中
2 期
EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER2024-514604-14-00Grupo Espanol De Oncologia Genitourinaria-Socug39
进行中（未招募）
1 期
EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCERMuscle-invasive bladder cancerCTIS2024-514604-14-00Grupo Espanol De Oncologia Genitourinaria-Socug39
已完成
不适用
Durvalmab plus platinum-etoposide versus atezolizumab plus platinum-etoposide in extensive- stage small cell lung cancer: a systematic review.extensive-stage (ES) small-cell lung cancer (SCLC) (ES-SCLC)JPRN-UMIN000040194Showa University School of Medicine940
进行中（未招募）
2 期
Combination Therapy with Atezolizumab plus Bevacizumab for TACE Unsuitable Patients in Intermediate Stage Up-to-Seven Out Hepatocellular Carcinoma - a phase II studyHepatocellular CarcinomaJPRN-jRCTs071200051Kudo Masatoshi70
进行中（未招募）
1 期
PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATIOMALIGNANT PLEURAL MESOTHELIOMA PATIENTSMedDRA version: 20.0Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003762-39-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)162